FDA Panel Votes to Keep Avandia on Shelves

Controversial diabetes drug still faces heart-attack link
By Sam Biddle,  Newser Staff
Posted Jul 30, 2007 5:38 PM CDT
FDA Panel Votes to Keep Avandia on Shelves
Food and Drug Administration Commissioner Andrew von Eschenbach holds up a copy of the Physicians Desk Reference book while testifying on Capitol Hill in Washington, Wednesday, June 6, 2007, before the House Oversight and Government Reform Committee hearing on the diabetes drug Avandia. (AP Photo/Susan...   (Associated Press)

(Newser) – An FDA panel said today that GlaxoSmithKline's diabetes drug Avandia should remain in drugstores, despite earlier evidence the pill ups heart failure risks. Glaxo has defended its drug, countering that the risks associated with the popular Avandia are the same as those of other diabetes drugs.

"None of these drugs are perfect," said a Glaxo senior VP. The FDA, which is not obliged to follow its panel's advice, has not come to any conclusion about whether the drug will be recalled. It has, however, proposed adding more prominent warning labels and even drawing up a patient registry. (Read more Avandia stories.)

We use cookies. By Clicking "OK" or any content on this site, you agree to allow cookies to be placed. Read more in our privacy policy.
Get the news faster.
Tap to install our app.
X
Install the Newser News app
in two easy steps:
1. Tap in your navigation bar.
2. Tap to Add to Home Screen.

X